In the responsive group, 9 mutations (26%) were found in genes concerning proliferation pathways: PIK3CA (2 ADC with exon 9 E545K, and a poorly differentiated carcinoma with H1047R), BRAF (V600E in 2 ADC), STK11 (V197fs 69 in one ADC and F354L in one SCC), NTRK2 (L755L in a SCC) and MET (N375S). This evidence concerns the gene MET and carcinoma.